NL-OMON43300已完成不适用
The NeuroFab Study: Two year follow-up of Cognitive and Psychological functioning in patients with Fabry Disease. - The NeuroFab Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Fabry patients:
- •* Signed informed consent
- •* Agreeing to be informed about medically relevant personal test-results by a physician
- •* Definite diagnosis of FD according to previously developed diagnostic criteria (see protocol: appendix A, Table 1. for diagnostic criteria).
排除标准
- •Subjects who meet any of the following criteria will be excluded from participation in this study:
- •Fabry patients:
- •* Unwillingness to participate
- •* Uncertain FD diagnosis (not fulfilling the criteria mentioned in protocol: appendix A, Table 1)
- •* Unable to execute approximately two hours of neuropsychological tests
- •* Medical conditions which make participation in the study not feasible (e.g. other diseases than FD affecting the brain), decided by a medical doctor during screening
- •* Clinically relevant comorbidities, not attributable to FD, presumably influencing neuropsychological test results
- •* Severe hearing loss and/or vision loss resulting in inability to complete neuropsychological tests and questionnaires
研究者
相似试验
招募中
不适用
An observational study for patients with cognitive impairments using an advanced MRI which can detect blood-brain barrier dysfunctionsPatients with cognitive impairmentsJPRN-UMIN000039724agoya City University100
招募中
不适用
Evaluation of Cognitive Behavioural Therapy programme for insomniaOther -InsomniaACTRN12605000668606Woolcock Institute of Medical Research300
已完成
不适用
Prospective observational study of the neurocognition in patients treated with prophylactic cranial irradiation in limited stage small cell lung cancer.JPRN-UMIN000037978ung Oncology Group in Kyushu, Japan (LOGIK)114
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-ATMerck Healthcare KGaA380
已完成
4 期
A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trialencephalomyelitis disseminataMultiple sclerosis (MS)10007963NL-OMON49089Merck9